The aim of the projects run within cancer metabolism platform is development of new anticancer drugs acting on biological targets associated with aberrant metabolic pathways in cancer cells (cancer metabolism). Dependence on specific metabolic pathways (e.g. glutaminolysis or glycolysis) is a feature of various types of cancer, therefore, targeting this vulnerability has potentially very broad application.
In October 2013, within the platform, Selvita started a strategic partnership with Merck KGaA (Germany). Jointly initiated research strategy assumed intensive development within several chemical series. The main goal of the project is to characterize a series of lead molecules with the proven mechanism of action and as the final step selection of candidates for further preclinical development.